Publication
The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects
Sipos, P. M., Loos, B. G., Abbas, F., Timmerman, M. F. & Velden, U. V. D., Jul-2005, In : Journal of Clinical Periodontology. 32, 7, p. 765-772 8 p.Research output: Contribution to journal › Article › Academic › peer-review
APA
Author
Harvard
Standard
The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects. / Sipos, P.M.; Loos, B.G.; Abbas, F.; Timmerman, M.F.; Velden, U. van der.
In: Journal of Clinical Periodontology, Vol. 32, No. 7, 07.2005, p. 765-772.Research output: Contribution to journal › Article › Academic › peer-review
Vancouver
BibTeX
}
RIS
TY - JOUR
T1 - The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects
AU - Sipos, P.M.
AU - Loos, B.G.
AU - Abbas, F.
AU - Timmerman, M.F.
AU - Velden, U. van der
N1 - Relation: https://www.rug.nl/ date_submitted:2007 Rights: University of Groningen
PY - 2005/7
Y1 - 2005/7
N2 - Objectives: The purpose of this split-mouth study was to evaluate the clinical response of enamel matrix proteins (EMPs, Emdogain Gel((R))) in intra-osseous defects with or without a combined application of a tetracycline-coated expanded polytetrafluoroethylene barrier membrane (e-PTFE, Gore-Tex((R))).Methods: Twelve pairs of intra-osseous periodontal defects in 11 patients received the application of EMPs on the exposed root surface (EMP). One of the two defects received randomly, as an adjunct to EMP treatment, a tetracycline-coated e-PTFE membrane (MEMP). At baseline, 6- and 12-month probing pocket depth (PPD), clinical attachment level (CAL) and probing bone level (PBL) were measured.Results: After 12 months, the EMP defects showed a significant mean PPD reduction of 2.86 +/- 0.75 mm, a mean gain in CAL of 1.28 +/- 2.04 mm, a mean PBL gain of 1.63 +/- 1.21 mm and a mean increase of recession (REC) of 1.56 +/- 2.30 mm. The MEMP defects showed a significant mean PPD reduction of 3.02 +/- 1.55 mm, a mean gain in CAL of 1.65 +/- 1.29 mm, a mean PBL gain of 1.58 +/- 1.92 mm and a mean increase of REC of 1.38 +/- 1.63 mm. Except for significantly more post-operative discomfort at the MEMP sites, no significant differences were found between EMP and MEMP defects.Conclusion: Within the limits of this study, it is concluded that in the treatment of intra-osseous defects with EMP, the adjunctive use of a tetracycline-coated e-PTFE membrane failed to show more gain of CAL and PBL.
AB - Objectives: The purpose of this split-mouth study was to evaluate the clinical response of enamel matrix proteins (EMPs, Emdogain Gel((R))) in intra-osseous defects with or without a combined application of a tetracycline-coated expanded polytetrafluoroethylene barrier membrane (e-PTFE, Gore-Tex((R))).Methods: Twelve pairs of intra-osseous periodontal defects in 11 patients received the application of EMPs on the exposed root surface (EMP). One of the two defects received randomly, as an adjunct to EMP treatment, a tetracycline-coated e-PTFE membrane (MEMP). At baseline, 6- and 12-month probing pocket depth (PPD), clinical attachment level (CAL) and probing bone level (PBL) were measured.Results: After 12 months, the EMP defects showed a significant mean PPD reduction of 2.86 +/- 0.75 mm, a mean gain in CAL of 1.28 +/- 2.04 mm, a mean PBL gain of 1.63 +/- 1.21 mm and a mean increase of recession (REC) of 1.56 +/- 2.30 mm. The MEMP defects showed a significant mean PPD reduction of 3.02 +/- 1.55 mm, a mean gain in CAL of 1.65 +/- 1.29 mm, a mean PBL gain of 1.58 +/- 1.92 mm and a mean increase of REC of 1.38 +/- 1.63 mm. Except for significantly more post-operative discomfort at the MEMP sites, no significant differences were found between EMP and MEMP defects.Conclusion: Within the limits of this study, it is concluded that in the treatment of intra-osseous defects with EMP, the adjunctive use of a tetracycline-coated e-PTFE membrane failed to show more gain of CAL and PBL.
KW - barrier membranes
KW - enamel matrix proteins
KW - GTR
KW - intra-osseous defects
KW - tetracycline
KW - GUIDED TISSUE REGENERATION
KW - INTRABONY PERIODONTAL DEFECTS
KW - CONTROLLED CLINICAL-TRIAL
KW - NON-RESORBABLE BARRIERS
KW - ANGULAR BONE DEFECTS
KW - IN-VITRO
KW - BIOABSORBABLE MEMBRANES
KW - DERIVATIVE EMDOGAIN(R)
KW - BACTERIAL-COLONIZATION
KW - ANAEROBIC-BACTERIA
U2 - 10.1111/j.1600-051X.2005.00754.x
DO - 10.1111/j.1600-051X.2005.00754.x
M3 - Article
VL - 32
SP - 765
EP - 772
JO - Journal of Clinical Periodontology
JF - Journal of Clinical Periodontology
SN - 0303-6979
IS - 7
ER -
ID: 2913241